常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.85/-0.94
|
|
企业价值
211.20M
|
| 资产负债 |
|
每股账面净值
0.49
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
8.00K
|
|
每股收益
0.30
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 15:50 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer. |

5.32 
